Tonix Pharmaceuticals Reports Q3 Revenue Beat Amid GAAP EPS Miss
Tonix Pharmaceuticals (TNXP) reported third-quarter financial results characterized by a significant surge in revenue alongside an earnings miss. The company posted net product revenue of approximately $17.2 million, representing a 423.7% increase compared to the $3.3 million recorded during the same period in the previous year. This figure exceeded analyst expectations by $0.91 million. Despite the top-line growth, Tonix reported a GAAP earnings per share (EPS) of -$2.89, missing consensus estimates by $0.50. The results highlight a period of rapid revenue scaling for the company, though profitability remains a challenge as net losses continue to impact the bottom line.
Tickers: $TNXP